- Home
- INKT vs INMB Comparison
INKT vs INMB Comparison
Compare INKT & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | INMB |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.9M | 45.7M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | INKT | INMB |
|---|---|---|
| Price | $10.60 | $1.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $35.00 | $5.40 |
| AVG Volume (30 Days) | 11.1K | ★ 767.1K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $8.48 | $1.09 |
| 52 Week High | $18.17 | $3.00 |
Technical Indicators
Market Signals| Indicator | INKT | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 49.70 |
| Support Level | $9.47 | $1.21 |
| Resistance Level | $12.61 | $1.76 |
| Average True Range (ATR) | 0.63 | 0.16 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 23.74 | 19.82 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.